[1] 温晓娜, 刘文生, 郭宏, 等. 质子泵抑制剂致药品不良反应分析[J]. 中国药房, 2012, 23(6):563-565. [2] 梁茂本, 孟祥梅. 114例质子泵抑制剂不良反应病例分析[J]. 中国药物警戒, 2013, 1(1):39-41. [3] 张树平, 李立宏. 药源性粒细胞减少症与粒细胞缺乏症研究现状[J]. 神经药理学报, 2005,22(6):80-82. [4] 徐薇. 药源性血液病[J]. 现代实用医学, 2005, 17(2):74-75. [5] 黄凯文. 药品不良反应知识概述[C]. 全国临床医学新进展(成都)学术研讨会, 2007. [6] 张建华, 齐晓涟. 注射用奥美拉唑致血液系统不良反应的调查分析[J]. 医药导报, 2007, 26(6):684-685. [7] Binnetoğlu E, Akbal E,Sen H, et al.Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding[J]. Platelets, 2015, 26(1):10-12. [8] Dury S, Nardi J, Gozalo C, et al.Agranulocytosis induced by proton pump inhibitors[J]. J Clin Gastroenterol, 2012, 46(10):859. [9] Gouraud, Aurore, Vochelle, et al. Proton Pump Inhibitor-Induced Neutropenia Possible Cross-Reactivity between Omeprazole and Pantoprazole[J]. Clinical Drug Investigation, 2010,30(8): 559-563. [10] Andres E, Maloisel F.Idiosyncratic drug-induced agranulocytosis or acute neutropenia[J]. Curr Opin Hematol, 2008, 15(1):15-21. [11] Aster R H, Curtis B R, McFarland J G, et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management[J]. J Thromb Haemost, 2009, 7(6):911-918. [12] 杨九一, 顾健. 药源性血小板减少症机制研究进展[J]. 中国医院药学杂志, 2013, 33(22):1874-1877. [13] George J N, Aster R H.Drug-induced thrombocytopenia: pathogenesis, evaluation, and management[R]. Hematology Am Soc Hematol Educ Program, 2009:153-158. [14] Hutchinson C 1, Geissler C A, Powell J J, et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis[J]. Gut, 2007, 56(9):1291-1295. [15] Sarzynski E, Puttarajappa C, Xie Y, et al.Association between proton pump inhibitor use and anemia: a retrospective cohort study[J]. Dig Dis Sci, 2011, 56(8):2349-2353. [16] 卢荣枝, 黎颖然. 注射用奥美拉唑钠致肝损害1例[J]. 中国药物警戒, 2010, 7(5):312. [17] Gomez M R, Otero M A, Fobelo M J, et al.Acute hepatitis related to omeprazole[J]. Am J Gastroenterol, 1999, 94(4):1119-1120. [18] 徐来凤, 张玉平, 郭秀兰. 1386例消化性溃疡的流行病学分析[J]. 中华消化内镜杂志, 2000, 17(3):184-185. |